One of the two drugs certified by the US Food and Drug Administration for the treatment of late stage African sleeping sickness caused by Trypanosoma brucei (T. brucei) is eflorinithine, a suicide inhibitor of ornithine decarboxylase (ODC), an enzyme in the polyamine biosynthesis pathway [10], further validate the importance of this pathway. The gene discussed is ODC1; the disease is human African trypanosomiasis.